SpayVac
Madison, US · 2 known investors
SpayVac develops single-dose, no-booster contraceptive vaccines for wildlife, livestock, aquaculture, and companion animals, using a proprietary liposome-based platform that produces a multi-year infertility immune response from one injection. The product is positioned as an alternative to surgical sterilization or vaccine-plus-booster fertility control methods.
Founders & leadership
TD
Thomas D'OrazioExecutive
MF
Mark FrakerExecutive
UB
Ursula BechertExecutive
Board
JR
Jeffrey RusinowBoard director
JP
Jeff PetersonBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$426.2K disclosed across 1 round · 2025
▶$426.2KraisedMay 2025 · 9 investors · Other Health CareRule 506(b)
▶$426.2KraisedMay 2025 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Thomas D'OrazioExecutive Officer, Director
- Jeffrey RusinowDirector
- Mark FrakerExecutive Officer
- Jeff PetersonDirector
- Ursula BechertExecutive Officer
- Offering amount
- $1M
- Amount sold
- $426.2K
- First sale
- May 2025
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does SpayVac do?
- SpayVac develops single-dose, no-booster contraceptive vaccines for wildlife, livestock, aquaculture, and companion animals, using a proprietary liposome-based platform that produces a multi-year infertility immune response from one injection. The product is positioned as an alternative to surgical sterilization or vaccine-plus-booster fertility control methods.
- Who are SpayVac's investors?
- SpayVac's investors include Central Texas Angel Network, Serra Ventures.
- How much funding has SpayVac raised?
- SpayVac has disclosed $426.2K raised across 1 round.
- Where is SpayVac headquartered?
- SpayVac is headquartered in Madison, US.